EBMT 2016

Dr Ocio, Universidad de Salamanca, Spain, speaks with ecancertv at EBMT in Valencia, Spain, reviewing the years developments in myeloma treatment, and looking forward to paths for future development in treatment constellations. Second generation proteasome inhibitors and acetylase inhibitors are among the novel drugs showing clinical promise, and autologous stem cell transplant continues to be effective in frontline and relapsed myeloma treatment.

Prof Richardson (Dana-Farber Cancer Institute, Boston, USA) talks to Prof Mohty (President of the European society for Blood and Marrrow Transplantation - EBMT) at this year's EBMT conference in Valencia, Spain, reviewing the conference highlights. With specific regard to myeloma, novel drugs including ibrutinib, carfilzomib, ixazomib, and the FDA approval of defibrotide to treat veno-occlusive disease (VOD), show great promise in reducing toxicity and increasing maintenance of patient survival. Cellular therapies and faecal transplantation are other novel techniques discussed at the conference, with notably reduced complications compared to current cytotoxic treatments Looking forward, the potential of chemotherapy-free treatment, a growing understanding of the microbiome and reducing the risk of secondary malignancies are fields of interest in the near future.